31 active not recruiting. 31 Phase 2, 5 Phase 1, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 31 | Active not recruiting 31 |
| Phase 1 | 5 | Active not recruiting 5 |
| Phase 3 | 3 | Active not recruiting 3 |
Follow Tauopathies: new trials by email Literature Review of Tauopathies trials Research Report on Tauopathies
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease VHB937, Placebo - Alzheimer's Disease | Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 97 | 2025-08-07 | 2026-10-21 |
| Use of a Product Containing the Cannabinoids CBD and THC as a Treatment Strategy for Alzheimer's Disease - Alzheimer's Disease and Cannabis Clinical Trial (DAZACANN) Open-Label Phase Cannabis 50 mg of CBD and 5 mg of THC - Alzheimer Disease (AD) | Phase 1 / Phase 2 | Active not recruiting | Federal University of Latin American Integration | 61 | 2025-04-07 | 2025-08-12 |
| A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease E2814, Lecanemab, Placebo - Alzheimer's Disease | Phase 2 | Active not recruiting | Eisai Inc. | 105 | 2024-09-30 | 2026-02-11 |
| Study of SPG302 in Adult Participants With Mild-to-Moderate Alzheimer's Disease (AD) SPG302, Placebo - Alzheimer Disease | Phase 2 | Active not recruiting | Spinogenix | 24 | 2024-07-29 | 2025-08-17 |
| A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP) FNP-223, Placebo - Progressive Supranuclear Palsy | Phase 2 | Active not recruiting | Ferrer Internacional S.A. | 241 | 2024-07-23 | 2025-10-15 |
| A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease JNJ-64042056, Placebo - Alzheimer Disease | Phase 2 | Active not recruiting | Janssen Pharmaceutica N.V., Belgium | 55 | 2024-07-22 | 2026-09-25 |
| A Study to Evaluate the Safety and Biomarker Effects of RO7269162 in Participants at Risk for or at the Prodromal Stage of Alzheimer's Disease (AD) RO7269162, Placebo - Alzheimer's Disease | Phase 2 | Active not recruiting | Hoffmann-La Roche | 256 | 2024-05-02 | 2026-08-12 |
| Effect of 10 mg Xanamem on Dementia Due to Alzheimer's Disease Xanamem, Placebo - Dementia Moderate, Dementia, Mild | Phase 2 / Phase 3 | Active not recruiting | Actinogen Medical | 247 | 2024-04-12 | 2026-10-21 |
| A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam) Low Dose Benfotiamine, High Dose Benfotiamine, Placebo - Alzheimer Disease | Phase 2 | Active not recruiting | Weill Medical College of Cornell University | 406 | 2024-03-28 | 2026-09-17 |
| Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease BMS-986446, Placebo - Alzheimer Disease, Early Onset | Phase 2 | Active not recruiting | Bristol-Myers Squibb | 310 | 2024-03-20 | 2025-07-24 |
| A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD) sabirnetug, Placebo - Alzheimer Disease | Phase 2 | Active not recruiting | Acumen Pharmaceuticals | 542 | 2024-02-29 | 2025-10-27 |
| Effects of a Widely Used Vaccine Adjuvant in Subjects With Early Alzheimer's Disease Double-blind Study to Assess the Safety and Efficacy of AD04 in Patients With Early Alzheimer's Disease - ADVANCE AD04, Placebo - Alzheimer Disease, Early Onset | Phase 2 | Active not recruiting | ADvantage Therapeutics | 122 | 2023-11-08 | 2025-08-06 |
| Allopregnanolone Regenerative Therapeutic for Mild Alzheimer's Disease Allopregnanolone, Placebo - Alzheimer Dementia, Late Onset Alzheimer Disease | Phase 2 | Active not recruiting | University of Arizona | 100 | 2023-08-15 | 2026-06-30 |
| Study in Subjects With Mild-to-Moderate Alzheimer's Dementia ALZN002 (autologous DCs pulsed with E22W mutant peptide)., Placebo - Alzheimer Disease | Phase 1 / Phase 2 | Active not recruiting | Alzamend Neuro, Inc. | 30 | 2023-07-05 | 2026-09-30 |
| Effect of Equol Supplementation on Arterial Stiffness and Cognition in Healthy Volunteers S-equol, Placebo - Arterial Stiffness, White Matter Lesions | Phase 2 | Active not recruiting | Akira Sekikawa | 369 | 2023-06-29 | 2026-08-20 |
| A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease CT1812, Placebo - Early Alzheimer's Disease | Phase 2 | Active not recruiting | Cognition Therapeutics | 540 | 2023-06-28 | 2026-08-10 |
| A Clinical Trial to Access Pharmacokinetic Profiles and Safety of IVL3003. Aricept Tablet, IVL3003 - Alzheimer Disease | Phase 1 / Phase 2 | Active not recruiting | Inventage Lab., Inc. | 62 | 2023-04-01 | 2024-12-19 |
| Impact of Intensive Treatment of SBP on Brain Perfusion, Amyloid, and Tau (IPAT Study) Angiotensin II Receptor Blockers (ARBs, losartan) and Calcium Channel Blockers (CCB, amlodipine), PCP - Cognitively Normal Older Adults, Hypertension | Phase 2 | Active not recruiting | Rong Zhang | 180 | 2022-10-25 | 2026-07-21 |
| Therapeutic Evaluation of Low-dose IL-2-based Immunomodulatory Approach in Patients With Early AD Proleukin, Placebo - Alzheimer Disease | Phase 2 | Active not recruiting | Centre Hospitalier St Anne | 40 | 2022-10-11 | 2026-07-22 |
| Clinical Trial on Agitation in Alzheimer's Dementia IGC-AD1-Active, IGC-AD1-Placebo - Alzheimer Disease, Agitation,Psychomotor | Phase 2 | Active not recruiting | IGC Pharma, LLC | 164 | 2022-10-11 | 2026-09-30 |
Showing 20 of 31. Sign in to see all of them.
Alzheimer Disease (30) · Dementia (9) · Cognitive Dysfunction (8) · Neurodegenerative Diseases (2) · Aggression (1) · Anxiety Disorders (1) · Brain Diseases (1) · Caregiver Burden (1) · Depression (1) · Disease Progression (1) · Hypertension (1) · Immunoglobulin Light-chain Amyloidosis (1) · Inflammation (1) · Lymphoma, Follicular (1) · Marijuana Abuse (1)
Central Nervous System Diseases (31) · Nervous System Diseases (31) · Brain Diseases (30) · Mental Disorders (30) · Neurocognitive Disorders (30) · Neurodegenerative Diseases (29) · Dementia (21) · Cognition Disorders (8) · Pathological Conditions, Signs and Symptoms (5) · Neurologic Manifestations (3) · Pathologic Processes (3) · Signs and Symptoms (3) · Immune System Diseases (2) · Immunoproliferative Disorders (2)
lecanemab (3) · Dasatinib (2) · Quercetin (2) · Sodium Chloride (2) · 4-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene (1) · Amlodipine (1) · Angiotensin Receptor Antagonists (1) · Calcium Channel Blockers (1) · Dexamethasone (1) · Donepezil (1) · Dronabinol (1) · Equol (1) · Exercise (1) · Interleukin-2 (1) · Losartan (1)
Washington University School of Medicine (3) · Hoffmann-La Roche (2) · Weill Medical College of Cornell University (2) · ADvantage Therapeutics (1) · Actinogen Medical (1) · Acumen Pharmaceuticals (1) · Akira Sekikawa (1) · Alzamend Neuro, Inc. (1) · Bristol-Myers Squibb (1) · Centre Hospitalier St Anne (1) · Cognition Therapeutics (1) · Columbia University (1) · Eisai Inc. (1) · Federal University of Latin American Integration (1) · Ferrer Internacional S.A. (1)
United States (24) · Spain (10) · Australia (9) · United Kingdom (9) · Canada (7) · France (7) · Germany (7) · Japan (7) · Italy (5) · Poland (5) · South Korea (4) · Brazil (3) · Netherlands (3) · Puerto Rico (3) · Sweden (3)
Randall J Bateman, MD (2) · Achim Schneeberger, MD (1) · Akira Sekikawa, MD, PhD, PhD (1) · Anelyssa D'Abreu, MD (1) · Anthony Caggiano, MD (1) · Brew Brew, MBBS,MD,DSC (1) · Carol Manning, PhD (1) · Dan Iosifescu, MD (1) · David Zhu, PhD (1) · Gary E. Gibson, PhD (1) · Gerson D Hernandez, MD, MPH (1)
PMID 34366147, PMID 34687726, PMID 36538409, PMID 37017737, PMID 38809849, PMID 39800458, PMID 39974075, PMID 40009460, PMID 40120616, PMID 40226119, PMID 40838083, PMID 40985290, PMID 41239890, PMID 42179865
2023 (4), R01AG046179 (2), R01AG053267 (2), R56AG053267 (2), U01AG042791 (2), U01AG059798 (2), 2018 (1), R01AG063826 (1), R01AG065248 (1), R01AG068319 (1), R01AG074971 (1), R01AG076634 (1), R01AG076660 (1), RF1AG070438 (1)